Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects (Q34496122)

2 August 2017

title

Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects (English)

1 reference

2 August 2017

0 references

1 reference

ChEBI release 2020-05-28

Kelly Kuk

1

1 reference

2 August 2017

Jennifer L Taylor-Cousar

series ordinal

2

1 reference

2 August 2017

publication date

28 September 2015

1 reference

Therapeutic advances in respiratory disease

2 August 2017

published in

1 reference

2 August 2017

volume

9

1 reference

2 August 2017

issue

6

1 reference

2 August 2017

page(s)

313-326

1 reference

Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

CYSTIC FIBROSIS OF THE PANCREAS AND ITS RELATION TO CELIAC DISEASE

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Intestinal complications of cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Abnormal localization of cystic fibrosis transmembrane conductance regulator in primary cultures of cystic fibrosis airway epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Mucus clearance and lung function in cystic fibrosis with hypertonic saline

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Moving forward: cystic fibrosis gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Regulation of CFTR Cl- channel gating by ATP binding and hydrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Identification of the cystic fibrosis gene: genetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Effect of high-dose ibuprofen in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Trends in the use of routine therapies in cystic fibrosis: 1995-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Longevity of Patients With Cystic Fibrosis in 2000 to 2010 and Beyond: Survival Analysis of the Cystic Fibrosis Foundation Patient Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

An 18‐month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Ataluren as an agent for therapeutic nonsense suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Identification of the cystic fibrosis gene: chromosome walking and jumping

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Altered protein folding may be the molecular basis of most cases of cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

Ivacaftor potentiation of multiple CFTR channels with gating mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1753465815601934

21 January 2018

Identifiers

DOI

10.1177/1753465815601934

1 reference

2 August 2017

1 reference